Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
A Phase II Study of Tegafur/Uracil (UFUR )Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary

ct scan
local therapy
hepatoma
hepatitis
neutrophil count
  • 4 views
  • 07 Nov, 2020
  • 1 location
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

/metastatic HCC with Child-Pugh B7 liver disease who have received no prior systemic therapy.

  • 0 views
  • 10 Apr, 2021
  • 1 location
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

For the majority of patients, metastatic HCC is incurable and patients should be considered candidates for clinical trials when appropriate. Till recently there was no worldwide, approved

platelet count
neutrophil count
cancer
coumadin
sorafenib
  • 14 views
  • 07 Nov, 2020
  • 1 location
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

hepatocellular carcinoma who could not be radically cured and not receive any prior systemic therapy. The study will use PFS and OS as the co-primary endpoints, with approximately 280 patients planned to be

  • 0 views
  • 03 Feb, 2021
  • 1 location
Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma

, additional preoperative intra- and extra-hepatic early or metastatic HCC unseen or equivocal with conventional imaging (CT and MRI) and responsible for recurrence or disease progression at 6 months.

  • 1 views
  • 31 Jan, 2021
  • 5 locations
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression

metastatic hepatocellular carcinoma
TACE
lenvatinib
hepatitis
chemoembolization
  • 79 views
  • 04 Aug, 2021
  • 178 locations
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

metastatic hepatocellular carcinoma, HCC). Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the

  • 0 views
  • 16 Jul, 2021
  • 58 locations
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different …

abdominal compartment syndrome
oxaliplatin
etoposide
tumor cells
cancer
  • 178 views
  • 01 Aug, 2021
  • 138 locations
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma

HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there is no effective systemic chemotherapy for HCC. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are both overexpressed in HCC and thought to contribute to tumor development. Oxaliplatin in combination with other chemotherapies or …

  • 1 views
  • 07 Nov, 2020
  • 1 location
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC

Hepatocellular carcinoma (HCC) is a common malignancy, and more than 70% of newly diagnosed HCC patients already have advanced disease. Sorafenib and lenvatinib are recommended as first-line options for advanced HCC. The PD-1 monoclonal antibodysuch as nivolumab and pembrolizumab, have been approved to treat the patients with advanced HCC by …

  • 0 views
  • 26 Jan, 2021
  • 1 location